Local immunomodulation for cancer therapy: Providing treatment where needed.
In murine models of cancer, we have achieved efficient systemic activation of tumor-specific T cells by the local administration of a CTLA4-blocking antibody at low doses. Using a slow-release formulation, we could drastically lower the serum levels of the antibody, hence decreasing adverse effects and the risk of autoimmune reactions, without losing systemic efficacy.
Department of Immunohematology and Blood Transfusion; Leiden University Medical Center; Leiden, The Netherlands.
Marieke F
MF
Fransen
Department of Immunohematology and Blood Transfusion; Leiden University Medical Center; Leiden, The Netherlands.
Ferry
F
Ossendorp
Department of Immunohematology and Blood Transfusion; Leiden University Medical Center; Leiden, The Netherlands.
Ramon
R
Arens
Department of Immunohematology and Blood Transfusion; Leiden University Medical Center; Leiden, The Netherlands ; ISA Pharmaceuticals; Leiden, The Netherlands.
Cornelis Jm
CJ
Melief
CTLA-4; abscopal effect; immunomodulating; local treatment; side-effects